| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Respiratory Medicine, Queen Elizabeth Hospital, Birmingham, UK.
Correspondence to: Simon Gompertz, MD, Lung Investigation Unit, First Floor, Nuffield House, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2 TH, UK; e-mail: sgomp{at}doctors.org.uk
Study objective: Patients with COPD classically have neutrophilic bronchial inflammation and raised airway concentrations of the neutrophil chemoattractant leukotriene B4 (LTB4). A small phase II trial was conducted to assess the effects of a leukotriene synthesis inhibitor on bronchial inflammation in patients with stable COPD.
Design: A randomized, double-blind, placebo-controlled, parallel-group study.
Setting: Respiratory medicine department of a university hospital.
Patients and intervention: Seventeen patients with chronic bronchitis and COPD (mean FEV1, 35.5% predicted; SD, 14.8% predicted) were randomized to receive 14 days of the oral leukotriene synthesis inhibitor BAYx1005 (500 mg bid) or placebo.
Measurements and results: Spontaneous sputum samples obtained at baseline and at the end of treatment were assayed for LTB4, myeloperoxidase (an indirect marker of neutrophil numbers and/or activation), and chemotactic activity (Boyden chamber). After 14 days, there were no significant differences (p > 0.05) in absolute LTB4 concentrations between the two treatment groups. However, BAYx1005 treatment produced a significantly greater median reduction in LTB4 of - 3.1 nM (interquartile range [IQR], - 9.6 to - 0.2 nM) vs 3.0 nM (IQR, - 0.3 to 8.5 nM) [p = 0.001], with concentrations decreasing from 8.0 nM (IQR, 4.3 to 24.4 nM) at baseline to 4.2 nM (IQR, 1.9 to 11.9 nM) at the end of treatment (p = 0.03). There were no changes in the placebo group and no differences in sputum myeloperoxidase concentration or chemotaxis between the two treatment arms (p > 0.05).
Conclusions: This small study suggests that a leukotriene synthesis inhibitor can produce modest reductions in some measures of neutrophilic bronchial inflammation in patients with COPD. This class of anti-inflammatory agent requires further study in larger numbers of patients to determine clinical benefit.
Key Words: bronchitis • COPD • inflammation • leukotriene B4 • neutrophils
This article has been cited by other articles:
|
|
 |
|
  K.-L. Huang, C.-W. Chen, S.-J. Chu, W.-C. Perng, and C.-P. Wu Systemic Inflammation Caused by White Smoke Inhalation in a Combat Exercise Chest, March 1, 2008; 133(3): 722 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes New approaches to COPD Eur. Respir. Rev., September 1, 2005; 14(94): 2 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Riccioni, C. Di Ilio, P. Conti, T. C. Theoharides, and N. D'Orazio Advances in Therapy with Antileukotriene Drugs Ann. Clin. Lab. Sci., October 1, 2004; 34(4): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Montuschi, S A Kharitonov, G Ciabattoni, and P J Barnes Exhaled leukotrienes and prostaglandins in COPD Thorax, July 1, 2003; 58(7): 585 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Balbi COPD: Is Chemotaxis the Key? Chest, April 1, 2003; 123(4): 983 - 986. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
